Table 3.
Duration of C5 inhibitors treatment.
| Patient no. | Discontinued/ongoing | Treatment duration | Renal outcome, last follow-up |
|---|---|---|---|
| 3 | Discontinued | 36 months postpartum | CR, NA |
| 4 | Discontinued | POD40 | CR, NA |
| 5 | Discontinued | 12 months postpartum | CKD, discharge |
| 9 | Discontinueda | POD14 | ESRD, 12 months |
| 10 | Discontinued | 6 dosesb | CR, 24 months |
| 12 | Ongoing | POD183 | CR, POD183 |
| 13 | Ongoing | POD183 | CR, POD183 |
| 18 | Discontinued | POD90 | CR, 12 months |
| 35 | Ongoing | POD20 | CR, POD20 |
| 36 | Discontinued | 4 doses | CR, POD20 |
| 40 | Ongoing | POD14 | CR, POD14 |
| 42 | Discontinued | 6 months postpartum | CR, 12 months |
CKD, chronic kidney disease; CR, complete remission; ESRD, end-stage renal disease; NA, not available; POD, postdelivery day.
a
By patient’s choice.
b
When CH50 reached below 10%, and hemodialysis could be discontinued.